0001209191-18-046792.txt : 20180815
0001209191-18-046792.hdr.sgml : 20180815
20180815162237
ACCESSION NUMBER: 0001209191-18-046792
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180814
FILED AS OF DATE: 20180815
DATE AS OF CHANGE: 20180815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MESSINA RICHARD
CENTRAL INDEX KEY: 0001179382
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10352
FILM NUMBER: 181021258
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVENUE
STREET 2: 24TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: JUNIPER PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000821995
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 592758596
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-639-1500
MAIL ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
FORMER COMPANY:
FORMER CONFORMED NAME: COLUMBIA LABORATORIES INC
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-14
1
0000821995
JUNIPER PHARMACEUTICALS INC
JNP
0001179382
MESSINA RICHARD
C/O JUNIPER PHARMACEUTICALS INC.
33 ARCH STREET SUITE 3110
BOSTON
MA
02110
1
0
0
0
Common Stock
2018-08-14
4
D
0
13657
11.50
D
0
D
Common Stock
2018-08-14
4
D
0
250
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
250
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
250
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
8000
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
9700
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
41000
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
14500
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
2001
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
28000
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
6250
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
875
11.50
D
0
I
See Footnote
Common Stock
2018-08-14
4
D
0
100000
11.50
D
0
I
See Footnote
Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
Includes 5,625 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 5,625 restricted stock units was cancelled in exchange for the Offer Price.
Shares held by Richard Messina CF Jacqueline Messina UTMA.
Shares held by Richard Messina CF Carolyn Messina UTMA.
Shares held by Richard Messina CF Madeline Messina UTMA.
Shares held by Equity TR Co TTEE FBO Pamela Brocious SEP.
Shares held by Steve A. Sanders and Partners.
Shares held by Citistaffing LLC Profit Sharing.
Shares held by Summit Capital Associates.
Shares held by Benchmark Pellinore Group.
Shares held by SCA Retirement Plan DTD 1/1/91.
Shares held by Pamela Brocious M/P PEN PL.
Shares held by SCA Money Purchase Plan DTD 1/1/94 Attn Richard Messina.
Shares held by The Benchmark Company LLC - Investment Purposes.
/s/ Jeffrey Young, Attorney-in-Fact
2018-08-15